Spacer (n = 39) | Control (n = 39) | P | |||
---|---|---|---|---|---|
n | % | n | % | ||
Age, years | |||||
Median (range) | 71 (55–79) | 69 (56–81) | 0.87 | ||
BMI, kg/m2 | |||||
Median (range) | 23.6 (19.7–29.7) | 24.2 (20.4–38.2) | 0.42 | ||
Performance status | |||||
0 | 15 | 38.5 | 16 | 41 | 1.0 |
1 | 24 | 61.5 | 23 | 59 | |
Pre-treatment PSA, ng/mL | |||||
Median (range) | 8.3 (2.3–195) | 8.6 (3.9–83.1) | |||
≤ 10 | 24 | 61.5 | 24 | 61.5 | 0.91 |
10–20 | 11 | 28.2 | 12 | 30.8 | |
20 > | 4 | 10.3 | 3 | 7.7 | |
Gleason score | |||||
6 | 3 | 7.7 | 5 | 12.8 | 0.36 |
7 | 24 | 61.5 | 28 | 71.8 | |
8 | 6 | 15.4 | 2 | 5.1 | |
9 | 6 | 15.4 | 4 | 10.3 | |
Clinical T stage | |||||
T1c | 8 | 20.5 | 13 | 33.3 | 0.49 |
T2a | 18 | 46.2 | 18 | 46.2 | |
T2b | 1 | 2.6 | 2 | 5.1 | |
T2c | 9 | 23.1 | 4 | 10.3 | |
T3a | 2 | 5.1 | 2 | 5.1 | |
T3b | 1 | 2.6 | 0 | 0 | |
Risk group | |||||
Low | 2 | 5.1 | 0 | 0 | 0.4 |
Intermediate | 25 | 64.1 | 30 | 76.9 | |
High | 6 | 15.4 | 4 | 10.3 | |
Very high | 6 | 15.4 | 5 | 12.8 | |
Concurrent androgen deprivation therapy | |||||
Yes | 23 | 59 | 21 | 53.8 | 0.82 |
No | 16 | 41 | 18 | 46.2 | |
PSA at RT initiation, ng/mL | |||||
Median (range) | 3.4 (0.02–16.3) | 3.6 (0.01–20.2) | 0.78 | ||
Anti-coagulation or platelet treatment | |||||
Yes | 6 | 15.4 | 5 | 12.8 | 1 |
No | 33 | 84.6 | 34 | 87.2 | |
Diabetes | |||||
Yes | 5 | 12.8 | 7 | 17.9 | 0.76 |
No | 34 | 87.2 | 32 | 82.1 |